What is Holobiome?
Holobiome operates at the intersection of biotechnology and human health, specializing in the discovery and development of first-in-class therapies derived from the human microbiome. By translating complex scientific insights into actionable, targeted health solutions, the company is positioning itself as a leader in the next generation of probiotic and wellness innovation. Founded by research scientists from Northeastern University, the organization leverages a deep understanding of gut microbes to address systemic medical challenges. Their strategic focus on the microbiome ecosystem allows for the creation of novel interventions that aim to improve patient outcomes across a spectrum of chronic conditions, effectively bridging the gap between academic research and commercialized therapeutic applications.
How much funding has Holobiome raised?
Holobiome has raised a total of $99K across 1 funding round:
Debt
$99K
Debt (2021): $99K with participation from PPP
Key Investors in Holobiome
PPP
Public-Private Partnership
What's next for Holobiome?
With this recent infusion of capital, Holobiome is well-positioned to scale its operational capabilities and advance its lead candidates through rigorous clinical validation. The company's strategic roadmap likely involves deepening its intellectual property portfolio and refining its discovery platform to identify new microbial strains with therapeutic potential. As the firm matures, the focus will shift toward establishing key partnerships and navigating the regulatory landscape to bring its innovative solutions to market. This phase of growth is essential for Holobiome to solidify its market position and demonstrate the long-term efficacy of its microbiome-centric approach to modern medicine.
See full Holobiome company page
